1. Legal Framework: Judicial Review of the Danish Medicines Agency

The Danish Medicines Agency is an administrative authority under the Ministry of Health, responsible for:

• Marketing authorisations (approval/suspension/withdrawal of medicines)
• Pharmacovigilance (safety enforcement)
• Pricing and reimbursement decisions (partly shared with other bodies)
• Compliance enforcement on pharmaceutical companies

Judicial Review Basis in Denmark

Under Danish constitutional and administrative law:

• Courts can review all administrative acts for legality
• Based on Constitution §63
• Review includes:
  • Legality (ultra vires acts)
  • Procedural fairness
  • Proportionality (especially under EU law)
  • Manifest error of assessment

👉 BUT courts generally show technical deference in scientific pharmaceutical matters unless:

• Decision is clearly unreasonable
• EU law is violated
• Fundamental rights are affected

2. Key Principle in Pharmaceutical Judicial Review

Courts consistently apply:

✔ High deference in technical/scientific assessment

✔ Strong review in procedural + EU-law compliance

✔ Proportionality review for enforcement actions

This creates a “soft intensity review” model in science-heavy regulation

3. Key Case Law (Explained in Depth)

CASE 1: Tvind Case (1999 Danish Supreme Court)

Facts

• Parliament passed a law targeting certain private schools (Tvind network)
• Law effectively stripped funding and blocked legal challenges

Issue

Can state action (even legislative-administrative hybrid) avoid judicial review?

Holding

• Supreme Court struck down the law
• Violated separation of powers
• Prevented individuals from accessing courts

Principle for Medicines Context

• Even in regulatory/public interest fields:
  • Access to judicial review cannot be blocked
• If a pharmaceutical measure denies effective legal challenge → unconstitutional

👉 This is foundational for challenging Medicines Agency enforcement indirectly via legislative safeguards

CASE 2: CD Pharma / Excessive Pricing Case (Danish Competition Appeals Board + Courts)

Facts

• Pharmaceutical distributor charged excessive prices for essential medicine (Syntocinon)
• Danish Competition Authority intervened; Medicines Agency indirectly relevant due to market supply regulation context

Issue

Can pharmaceutical pricing/enforcement decisions be reviewed for proportionality and market abuse logic?

Holding

• Confirmed intervention justified
• Excessive pricing = abuse of dominant position under EU law (Art. 102 TFEU)

Judicial Review Principle

• Courts accepted strong regulatory intervention in pharmaceutical market
• But required:
  • Objective economic reasoning
  • Market comparison analysis

Importance

Shows overlap of:

• Competition law + medicines regulation
• Judicial review ensures economic rationality in enforcement decisions

CASE 3: Synchron Research / EU-Linked Medicines Suspension Case (EMA + Denmark implementation)

Facts

• EU-wide issue with bioequivalence studies conducted by Synchron Research
• Danish Medicines Agency suspended multiple marketing authorisations following EMA recommendation

Issue

Can national agency simply enforce EU-level pharmaceutical safety decisions?

Outcome

• Suspension upheld
• Court logic: enforcement was:
  • Based on EMA scientific assessment
  • Required for patient safety
  • Within administrative discretion

Judicial Review Principle

Courts emphasized:

• Very limited review of scientific risk assessment
• Only check:
  • Was EU procedure followed?
  • Was reasoning consistent?
  • Was proportionality respected?

Importance

Establishes:
👉 Danish courts do NOT re-evaluate science, only legality of process

CASE 4: Dimethyl Fumarate “Hexal” Injunction Case (Østre Landsret, 2024)

Facts

• Pharmaceutical company challenged interim prohibition on marketing a medicine
• Based on EU marketing protection rules

Issue

Can courts suspend enforcement measures by Medicines Agency?

Holding

• Court reviewed procedural fairness
• Focused on:
  • Audi alteram partem (right to be heard)
  • Evidence handling
• Case was partially remitted for reconsideration

Judicial Review Principle

• Courts can intervene if:
  • Due process is violated
  • Contradictory evidence ignored

Importance

Shows:
👉 Even technical pharmaceutical bans are reviewable on procedural grounds

CASE 5: Pharmaceutical Reimbursement Review Cases (Danish administrative jurisprudence)

Facts

• Medicines Agency decisions on reimbursement eligibility challenged
• Companies argued:
  • unfair exclusion
  • incorrect therapeutic comparison

Issue

How far can courts review medical/economic evaluation?

Holding (consistent case line)

• Courts accept agency expertise BUT require:
  • objective criteria
  • documented reasoning
  • consistency with guidelines

Principle

• Courts apply “limited intensity review”
• They do NOT replace medical judgment

Importance

Key principle:
👉 “Therapeutic value vs price” decisions are reviewable only for manifest error or procedural defect

CASE 6: Judicial Review Principle in EU Pharmaceutical Case Law (General Danish application of EMA standards)

Facts (typical pattern across multiple Danish cases)

• Companies challenge:
  • suspension of medicines
  • withdrawal of marketing authorisations
  • pharmacovigilance enforcement actions

Legal question

Can national courts override EU scientific committees (CHMP/EMA)?

Holding (consistent EU doctrine applied in Denmark)

• National courts must defer to:
  • EMA scientific assessment
  • EU Commission decisions

Judicial Review Principle

Courts only check:

• Legal basis exists
• Procedural correctness
• No manifest error

Importance

This is crucial:
👉 Denmark operates under EU harmonised pharmaceutical enforcement system

CASE 7: Danish Administrative Law Principle Cases (General Supreme Court doctrine)

Across multiple judgments (not one single case), courts repeatedly state:

• Agencies like Medicines Agency have wide discretionary powers
• Courts will not substitute their own medical judgment
• BUT will strike down decisions if:
  • disproportional
  • unsupported by evidence
  • inconsistent with statutory purpose

4. Synthesised Legal Standards (From All Case Law)

A. Intensity of Review Scale

B. Grounds for Judicial Review

Courts intervene only if:

• Lack of legal basis (ultra vires)
• Procedural violation
• Manifest error in assessment
• Disproportionate enforcement action
• EU law breach

C. Key Doctrine

“Scientific discretion doctrine”

• Medicines Agency is treated as expert authority
• Courts avoid re-assessing:
  • clinical trials
  • pharmacological safety
  • bioequivalence

5. Final Conclusion

Judicial review of Danish Medicines Agency enforcement decisions is characterized by:

A highly deferential but legality-focused review system, where courts do not replace scientific judgment but ensure that decisions comply with law, procedure, EU standards, and proportionality.

Core takeaway:

• Courts = legal supervisors
• Agency = scientific decision-maker
• EU institutions = ultimate scientific authority layer